Supernus Pharmaceuticals, Inc. / Sage Therapeutics, Inc.

Postpartum Depression (PPD)

500K US cases/yr · $250M Zurzuvae (zuranolone) US net product revenue, 2024 (Sage/Biogen reported) · ~13% Prevalence of PPD among US women with recent live birth (CDC PRAMS)

Disease Overview

Postpartum depression is a major depressive disorder with peripartum onset that affects women during pregnancy or within four weeks (DSM-5) to one year (clinical convention) of childbirth. PPD is distinct from the transient 'baby blues' in severity, duration, and functional impact: symptoms include persistent sadness, anxiety, anhedonia, suicidal ideation, impaired bonding, and cognitive dysfunction that disrupts maternal caregiving. The Centers for Disease Control and Prevention estimates that approximately 1 in 8 US women with a recent live birth report PPD symptoms, translating into roughly 400,000-500,000 affected mothers annually out of ~3.6M US births. PPD is the leading medical complication of childbirth and a driver of maternal suicide, which now ranks among the top causes of maternal mortality in the year following delivery. Historic standard of care has been SSRIs (4-8 week onset) and psychotherapy; neither addresses the acute GABAergic dysregulation hypothesis. The approval of brexanolone IV (Zulresso, 2019) and zuranolone (Zurzuvae, 2023) validated the neurosteroid GABA-A positive allosteric modulator thesis with rapid-onset symptom relief.

Competitive Landscape

The PPD treatment landscape is bifurcated between chronic antidepressants and rapid-acting neurosteroid GABA-A PAMs. Brexanolone (Zulresso, Sage 2019) was the first FDA-approved PPD therapy but required 60-hour inpatient IV infusion, capping utilization. Zuranolone (Zurzuvae, Sage/Biogen 2023) is the first oral therapy with a 14-day course and 3-day symptom-onset data from SKYLARK and ROBIN trials. Japan launch is gated on Shionogi partnership approval. Off-label SSRIs (sertraline, fluoxetine, escitalopram) remain first-line for mild-moderate PPD due to cost and access, with 4-8 week onset. Pipeline entrants include Relmada Therapeutics' esmethadone (REL-1017, NMDA antagonist, Phase 3 readouts delayed), Axsome's Auvelity (dextromethorphan/bupropion, MDD-approved, PPD exploratory), and Praxis Precision Medicines' PRAX-114 (extrasynaptic GABA-A PAM, discontinued for MDD 2023). Sage's own SAGE-718 (NMDA PAM) targets cognitive disorders rather than PPD. Supernus gains a defensible rapid-onset oral franchise with limited near-term biosimilar or mechanistic competition in the neurosteroid class.